Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yaz "approvable" again

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Schering AG subsidiary Berlex continues to expect a first-quarter 2006 decision on the low-dose oral contraceptive Yaz (ethinyl estradiol 20 mcg/drospirenone 3 mg) following receipt of a second "approvable" letter Jan. 23. The NDA for the low-dose formulation of the firm's successful Yasmin product "is approvable pending [FDA's] review of recently submitted data and their satisfactory conclusion of its content," Berlex says. The approvable decision pertains primarily to additional data regarding patients with premenstrual dysphoric disorder. FDA extended Yaz' PDUFA date in December following submission of additional data (1Pharmaceutical Approvals Monthly December 2005, In Brief)...

You may also be interested in...



Berlex Yaz 90-day extension

Schering AG subsidiary Berlex expects approval of its low-dose Yasmin formulation Yaz (ethinyl estradiol 20 mcg/drospirenone 3 mg) in the first quarter of 2006, the firm says Dec. 9 after a 90-day extension of the oral contraceptive's PDUFA date. Berlex says that "shortly after" receipt of a November 2004 "approvable" letter, it submitted information on the formulation's dosing regimen (24 days of active pills, 4 days inactive) as well as data to support an additional indication for premenstrual dysphoric disorder...

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel